Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2017

View Archived Issues

GSK reflects on accomplishments of second quarter 2017

Takeda presents key events of first quarter of fiscal 2017

Exposure to MeNZB vaccine associated with reduced rates of gonorrhea diagnosis

First-in-human results for personalized RNA mutanome vaccine IVAC MUTANOME

FDA grants priority review to RBP-6000 NDA, clearance for buprenorphine assay

Kite Pharma submits MAA to EMA for axicabtagene ciloleucel

PellePharm announces topline phase II data for topical patidegib in Gorlin syndrome

Syndros, the first and only FDA-approved liquid dronabinol, becomes available by prescription

BLU-667, a RET inhibitor, shows promise for RET-driven thyroid cancer

Antigen Express and Merck & Co. agree to test AE-37 with Keytruda in triple-negative breast cancer

BLA submission for trastuzumab biosimilar ABP-980

Isogenica licenses antibody libraries to Takeda

FDA grants orphan drug designation to RA-101495 for PNH

Bayer discloses soluble guanylate cyclase activators

Aerie collaborates with DSM on technology to deliver compounds for retinal diseases

FDA accepts for review BLA for trastuzumab biosimilar CT-P6

Chemerin receptor antagonists presented by Shenzhen Institute of Advanced Technology

Celgene details pipeline developments of second quarter 2017

Recro submits NDA for intravenous meloxicam for postoperative pain

Phase III MAP US study of RHB-104 in Crohn's disease cleared to continue

New tau PET ligands [18F]AM-PBB3 and [18F]PM-PBB3 evaluated in humans

Bristol-Myers Squibb and Clovis sign clinical collaboration agreement to test Opdivo with Rubraca

FDA clears IND for phase I study of PTI-125 for Alzheimer's disease

Intercept reports results from trials of obeticholic acid in PSC and NASH

Emergent BioSolutions' development of auto-injector for nerve agent antidote gets financial support

Kitov announces NDA submission for KIT-302

Loxo to acquire Redx's BTK inhibitor program

FDA awards breakthrough therapy designation to acalabrutinib for mantle cell lymphoma

Lumosa initiates phase I trial of LT-3001 for acute ischemic stroke

Nerlynx launched in U.S.

Astellas seeks Japanese approval for fidaxomicin for infectious enteritis caused by C. difficile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...